Evidence map›Paper›PMID 31104627›Full record

ArticleCurrent Alzheimer research2019

Lessons from Alzheimer's Disease (AD) Clinical Trials: Instead of "A-Drug", AD-D prevention to Avert AD.

Debomoy K Lahiri

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Current Alzheimer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Debomoy K LahiriDepartment of Psychiatry Indiana Alzheimer Disease Center Indiana University School of Medicine Indianapolis, IN-46202, United States.

Funding

Research Education ComponentP30AG010133 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI SAYKIN, ANDREW J · 1991 to 2020
$37.3M
Neurobiological Role of MicroRNA in Alzheimer'sR01AG051086 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI LAHIRI, DEBOMOY K · 2015 to 2019
$1.9M
Testing a Novel Approach to Solve the On-target, Off-site Effects of Alzheimer's DrugsR21AG056007 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI LAHIRI, DEBOMOY K · 2019 to 2020
$435k
Human MicroRNA as a potential therapeutic target in Alzheimer's disease.R21AG042804 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI LAHIRI, DEBOMOY K · 2012 to 2013
$411k
NIA NIH HHS P30 AG010133NIA NIH HHS R01 AG051086NIA NIH HHS R21 AG042804NIA NIH HHS R21 AG056007
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Alzheimer DiseaseClinical Trials as TopicHumans

Identifiers

PMID31104627
PMCPMC8462483

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.